Depression relapse is more common than most people expect, and experiencing one doesn’t mean care has failed. Stopping antidepressants too early is one of the most consistent predictors of symptoms returning, while continuing depression treatment through the maintenance phase meaningfully lowers that risk. A relapse is often a signal that the plan needs refining, not that a person must start from scratch.
This article walks through what that process looks like: how clinicians reassess, what changes in medication and therapy, and how care gets shaped toward longer-term stability.
Quick Answer Summary
After a depression relapse, clinicians reassess symptoms, functioning, and potential underlying factors before adjusting treatment. This may involve changing medications, modifying therapy approaches, increasing monitoring, or introducing advanced treatments like TMS or esketamine. The goal is to refine the care plan for long-term stability rather than restart treatment from the beginning.
Key Takeaways
- Depression relapse is common and often signals the need to adjust treatment rather than restart it.²
- Nearly 88% of individuals with depression report difficulty in daily functioning, highlighting the need for comprehensive care plans.¹
- Medication strategies after relapse may include dose adjustments, switching medications, or augmentation depending on patient history.²
- Augmentation strategies can be effective, with studies showing higher remission rates when adding medications compared to switching in some cases.²
- Therapy often shifts toward relapse prevention, using approaches like CBT, interpersonal therapy, and mindfulness-based cognitive therapy.⁵
- Close monitoring is standard after treatment changes, especially to assess symptom progression and safety risks.⁶
- Advanced treatments such as esketamine, TMS, or ECT may be introduced when standard approaches are insufficient.⁶
- Maintaining treatment after remission significantly reduces relapse risk, emphasizing the importance of long-term care planning.³
First, a Full Reassessment
A relapse visit is rarely a quick check-in. Before adjusting anything, clinicians typically take stock of where symptoms stand and what may have shifted since the last stable period.
That review can include PHQ-9 scores, sleep patterns, appetite, energy, motivation, medication adherence, side effects, substance use, recent stressors, and whether any new medical issues have emerged. Suicidal thoughts are always part of that conversation.
According to a 2025 CDC/NCHS Data Brief, 87.9% of people with depression reported at least some difficulty with work, home, or social activities. That means a depression treatment plan must address daily function, not just how someone scores on a checklist.
The original diagnosis may also get a second look. Clinicians sometimes use a relapse as an opportunity to rule out conditions like bipolar disorder or thyroid dysfunction, things that can look like recurrent depression but respond differently to care.
How Medication Plans Typically Change
Relapse doesn’t come with a universal medication playbook. Every decision starts with a history of what the patient responded to, what got stopped, and what the circumstances were.
The American College of Physicians’ 2023 living clinical guideline lays out the realistic range of depression treatment options: going back to a medication that worked before, adjusting the current dose, trying a different antidepressant altogether, or layering in a second agent. None of those paths is automatically right. The clinician has to weigh severity, past side effects, other medications, and what someone can honestly stick to.
Older adults are a separate conversation. The OPTIMUM trial followed 619 adults aged 60 and older with treatment-resistant depression. Augmenting with aripiprazole produced remission in 28.9% of patients; switching to bupropion hit only 19.3%. Sometimes adding is better than replacing.
Worth noting is that CDC/NCHS data from 2025 puts prescription depression treatment use at 11.4% of U.S. adults. Medication adjustments happen constantly, but most people just don’t hear about the process until they’re in it.
How Therapy May Shift After Relapse
Relapse often changes what therapy is for. The work tends to move from processing current distress toward building concrete skills for staying stable.
The VA/DoD Clinical Practice Guideline recommends offering cognitive behavioral therapy, interpersonal therapy, or mindfulness-based cognitive therapy during the continuation phase after remission, particularly for patients with a history of multiple episodes. CBT targets thought patterns and behaviors. Interpersonal therapy focuses on relationships and life transitions. Mindfulness-based cognitive therapy builds awareness of early warning signals. None of the three is ranked above the others; the choice depends on the patient.
Session content may also expand. Identifying personal relapse triggers, strengthening coping skills, behavioral activation, and safety planning are all common additions. Frequency may temporarily increase, then step down as stability returns. Psychiatric treatment and therapy often run in parallel by adjusting both at the same time rather than waiting to see how one goes before touching the other.
Safety Monitoring Is Always Part of the Adjustment
Any change to a depression treatment plan, especially when medication is being added, adjusted, or restarted, means closer monitoring. That’s not an alarm bell. It’s standard practice.
FDA antidepressant labeling, drawn from pooled data across approximately 77,000 adult patients, advises clinicians to watch for clinical worsening and emerging suicidal thoughts, particularly in early treatment changes. The VA/DoD guideline recommends monitoring at least monthly after any plan change, using PHQ-9 scores alongside side effect review and adherence checks.
Relapse is a vulnerable period. Structured check-ins give both the patient and provider the information needed to course-correct quickly if something shifts in the wrong direction.
Advanced Options When Standard Adjustments Aren’t Enough
Sometimes a dose change and a modified therapy approach still aren’t enough. For patients with recurrent or treatment-resistant depression, that’s when more advanced depression treatment options come into the picture.
Those include esketamine (Spravato), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or referral to specialty psychiatric treatment. The FDA Spravato label (2025) found that esketamine maintenance therapy significantly delayed relapse in patients who had responded to initial treatment. The estimated hazard ratio was 0.49, meaning those who continued Spravato were roughly half as likely to relapse as those switched to placebo nasal spray. It’s a meaningful number, though the FDA notes the effect wasn’t constant across the full trial period.
These aren’t last resorts. They’re thoughtful next steps when earlier data makes a compelling case for escalating care.
What Patients Can Do to Build Long-Term Stability
Getting stabilized is one thing. Staying there takes a different kind of effort, and it’s something clinicians and patients work on together.
The VA/DoD guideline recommends staying on antidepressants at a therapeutic dose for at least six months post-remission, longer for recurring depression.
Tracking also helps. A simple mood log, sleep notes, or a running list of stressors gives clinicians something real to work with, and gives patients a shot at catching warning signs early.
Therapy during this phase often shifts toward maintenance, with less focus on acute distress and more on preserving function and recognizing patterns. For patients who struggle to attend consistently, teletherapy can fill the gap. Telehealth is a practical delivery option for ongoing sessions, psychiatric evaluations, and monitoring. When life gets complicated, continuity matters more than format.
| Treatment Area | Before Relapse | After Relapse |
|---|---|---|
| Assessment | Routine symptom check-ins | Comprehensive reassessment including function, risk, and contributing factors |
| Medication | Stable dose or maintenance phase | Dose changes, switching, or augmentation strategies |
| Therapy Focus | Managing current symptoms | Relapse prevention, coping skills, trigger identification |
| Session Frequency | Reduced or maintenance frequency | Often increased temporarily, then tapered |
| Monitoring | Periodic follow-ups | Closer monitoring with symptom tracking and safety checks |
| Advanced Options | Not typically needed | May include TMS, esketamine, ECT, or specialty care |
Your Plan Can Evolve With You, Let Zeam Guide the Way
Relapse is not a verdict. It’s information, and it gives clinicians what they need to make a depression treatment plan more precise, more durable, and better matched to where a patient is now.
With careful reassessment, adjusted medication, targeted therapy, safety monitoring, and a longer view of care, most people can return to stability. At Zeam, our team in Sacramento, Folsom, and Roseville works across the full range of depression treatment, from ongoing psychiatric treatment and CBT to TMS, ketamine therapy, and Spravato. If you’ve experienced a relapse and are ready to take the next step, contact us today to schedule a consultation. We’ll meet you where you are and build from there.
Citations
- CDC/NCHS Data Brief (2025 – Functional Impairment in Depression): https://www.cdc.gov/nchs/products/databriefs/db527.htm
- American College of Physicians Clinical Guideline (2023): https://experts.umn.edu/en/publications/nonpharmacologic-and-pharmacologic-treatments-of-adults-in-the-ac/
- Depression Treatment Continuation and Relapse Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/
- CDC/NCHS Data Brief (2025 – Antidepressant Use): https://www.cdc.gov/nchs/products/databriefs/db528.htm
- VA/DoD Clinical Practice Guideline for Depression: https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf
- FDA Spravato (Esketamine) Label (2025): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
